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Prognostic Factors According to the Treatment Schedule in
Malignant Pleural Mesothelioma
Guntulu Ak, MD,* Selma Metintas, MD,† Muzaffer Metintas, MD,* Huseyin Yildirim, MD,*
Sinan Erginel, MD,* Emel Kurt, MD,* Fusun Alatas, MD,* and Omer Cadirci, MD*
Objectives: In this study, we aimed to investigate the factors affecting
the survival of patients with malignant pleural mesothelioma (MPM)
according to their treatment schedules, including those treated with best
supportive care, chemotherapy, and multimodality therapy.
Methods: We evaluated 235 patients with MPM. The patients were
classified into three groups according to their treatment schedules:
the best supportive care group, the chemotherapy group, and the
multimodality therapy group. Prognostic factors were determined
for all patients and for the three groups by univariate and multivar-
iate analyses. However, the effectiveness of treatment schedules as
a prognostic factor was not evaluated in this study.
Results: After adjusting for therapy in a Cox model, a Karnofsky
Performance Status (KPS) 70, a right side tumor, serum lactate
dehydrogenase 500 IU1, a nonepithelial subtype, and stage 3 to
4 disease were determined by multivariate analyses to be unfavor-
able prognostic factors for all the patients. A KPS 70, serum
lactate dehydrogenase 500 IU1, a nonepithelial subtype, and
stage 3 to 4 disease were associated with a poor prognosis for the
best supportive care group. The single unfavorable prognostic factor
for the chemotherapy group was a KPS 70. A right side tumor and
a nonepithelial subtype were associated with a poor prognosis for
the multimodality therapy group.
Conclusions: The patients with an epithelial subtype, a good KPS,
and an early-stage tumor had a good prognosis, even if they did not
receive any treatment. The only prognostic factor for the chemo-
therapy group was KPS. The histologic subtype and stage of the
tumor were not related to the prognosis in this group. A mixed
subtype and a right side tumor were unfavorable prognostic factors
for the multimodality therapy group. These findings may be useful
in counseling patients and in planning further studies.
Key Words: Malignant pleural mesothelioma, Prognostic factors,
Treatment schedule.
(J Thorac Oncol. 2009;4: 1425–1430)
Malignant pleural mesothelioma (MPM) is an uncommontumor of the pleura that is usually associated with a
poor prognosis. The incidence of MPM is still increasing
throughout most of the world, and it is expected to rise in the
coming decades.1 Until recently, no particular therapies have
been accepted as a standard of care due to the resistance of the
tumor to treatment modalities. However, some authors suggest
that the new chemotherapeutic agents and the therapeutic com-
bination of surgery, chemotherapy, and radiotherapy have re-
sulted in an increased survival for patients with MPM.2–7
The overall survival of patients with MPM varies
among the different available treatment strategies. However,
the treatment of patients with MPM depends on several
parameters including performance status, medical comorbidi-
ties, pulmonary function, tumor stage, and age. These factors
are also prognostic factors for MPM, and it is important to
identify them. These prognostic factors allow the selection of
patients more likely to benefit from more intensive treatment,
and this more accurate patient selection contributes to better
survival, with lower morbidity and mortality rates. Both the
European Organization for Research and Treatment of Can-
cer and the Cancer and Leukemia Group B examined the
effect of various pretreatment clinical characteristics on the
survival of patients with MPM who received chemotherapy.8,9 In
the European Organization for Research and Treatment of
Cancer study, poor prognosis was associated with a poor
performance status, a high white blood cell (WBC) count, a
probable/possible histologic diagnosis of mesothelioma, male
gender, and having sarcomatous tissue as the histologic
subtype.8 The Cancer and Leukemia Group B showed that
pleural involvement, serum lactate dehydrogenase (LDH)
level 500 IU/L, poor performance status, chest pain, plate-
let count 400,000 L1, nonepithelial histology, and age
more than 75 years predict poor survival.9
Most prognosis analyses have evaluated all patients as
a single group with no attention paid to treatment differences.
However, different antitumoral treatments may influence
prognosis. Additionally, the features of different treatment
groups vary from one another. For example, patients who
received multimodal treatment were younger, had a better
performance status, and had mostly epithelial type tumors of
an early stage.5
We hypothesized that the prognostic factors could be
determined according to the different treatment schedules,
including best supportive care, chemotherapy, and multimo-
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dality therapy, thereby allowing a more suitable selection of
patients for treatment and a more accurate estimation of
prognosis. Thus, the morbidity, mortality, and cost due to
treatment could subsequently be decreased and survival could
be improved. In this study, we aimed to investigate the
various pretreatment clinical and laboratory characteristics
affecting the survival of patients with MPM according to their
treatment schedules, including those treated with best sup-




Between January 1991 and June 2008, 274 patients
with MPM were diagnosed in our clinic. After diagnosis, best
supportive care, chemotherapy, or multimodality therapy was
performed on the patients. There were 39 patients who were
excluded for the analysis, including patients who had re-
ceived prior therapy, pleurectomy decortication, or pleurec-
tomy decortication plus chemotherapy. In addition, patients
who were not followed up, died within 30 days after diagno-
sis, died due to reasons unrelated to MPM (treatment com-
plication, pneumonia, pulmonary embolism, etc.) and those
who received only one or two cycles of chemotherapy with-
out measured response were excluded.
In this study, 235 patients were evaluated. Tumors from
all patients were staged according to the International Union
Against Cancer staging system. The patients were classified
into three groups according to their treatment schedule: the
best supportive care group (71 patients), the chemotherapy
group (147 patients), and the multimodality therapy group
(17 patients). Chemotherapy was given between 1990 and
1996 as cisplatin  mitomycin C  recombinant interferon
alpha 2a, between 1996 and 2000 as cisplatinmitomycin C
ifosfamide, between 2000 and 2005 as cisplatin  gemcitab-
ine, and since 2005 as cisplatin  pemetrexed. Surgical
resection consisted of extrapleural pneumonectomy with en
bloc resection of the lung, parietal pleura, hemipericardium,
and diaphragm. A systematic hilar and mediastinal lymphad-
enectomy was conducted. The diaphragm and pericardium
were reconstructed using mesh. Adjuvant radiotherapy was
delivered to the hemithorax, the thoracotomy incision, and at
the sites of chest drains.
Pretreatment Patient Characteristics
First, the prognostic factors were determined for all
patients. These factors were then also determined for each
treatment group, including the best supportive care group, the
chemotherapy group, and the multimodality therapy group,
by univariate and multivariate analyses. The following pre-
treatment characteristics were evaluated for prognostic im-
portance: age (75/75 years), gender, asbestos exposure
(yes/no), smoking history, presence of chest pain, presence of
dyspnea, weight loss in past 6 months (5% loss of body
weight/none or 5%), Karnofsky Performance Status (KPS)
(70/70), primary site of disease (right/left), platelet
count (400 000/400,000 L1), WBC count (10,000/
10,000 L1), hemoglobin level (12.8/12.8 g/dl), se-
rum LDH level (500/500 IU1), histologic subtype, and
stage. All prognostic indices were evaluated as categorical
variables. Continuous variables were categorized into two
groups. The cutoff points chosen were based on previous stud-
ies.8,9 However, the median values were used as the cutoff point
for both the hemoglobin level and the WBC count.
Statistical Analysis
Characteristics of the patients according to their treat-
ment schedule were compared using analysis of variance and
2 test. Survival curves were estimated using the Kaplan-
Meier method. Survival was measured from the date of
diagnosis. All the patients were followed until death or for a
minimum period of 1 year. Dates of death were verified
through the National Population Registry System. Compari-
sons for survival were performed using log-rank tests. The
proportional hazards regression model with stratification for
the clinical trial was used for both univariate and multivariate
analyses. Univariate analysis examined the prognostic impor-
tance of all factors. The Cox proportional hazard model was
used to examine variables. A two-sided test was used at a
0.05 level of significance. A step-down/step-wise variable
selection procedure was used to fit the multivariate model.
Only parameters that had p values 0.10 in the univariate
analysis used in the final model for multivariate analysis. The
importance of a prognostic factor was assessed by the p value
of the Wald 2 statistic, the relative risk (risk in patients in a
given category, when compared with the reference one), and
the 95% confidence interval. Statistical analyses were per-
formed using SPSS statistical software.
RESULTS
Patient Demographics
Patient characteristics are summarized in Table 1. The
mean age and mean KPS were found to be different among
the three groups. The presence of weight loss at diagnosis and
the tumor stage were also different between the multimodal-
ity therapy group and the other two groups but were not
different between the best supportive care and the chemo-
therapy group. The overall median survival time of all pa-
tients was 10.0 months. The median survival times were 7.0,
11.5, and 21.0 months for the best supportive care group, the
chemotherapy group, and the multimodality therapy group,
respectively (Figure 1).
Univariate Analysis Results
In univariate analysis, poor prognosis was associated
with the presence of weight loss (p  0.031; 9.0 versus 12.0
months), a poor KPS (p  0.0001; 4.5 versus 12.0 months),
a right site tumor (p  0.012; 9.0 versus 12.0 months), a high
WBC count (p  0.0001; 6.0 versus 12.0 months), a high
LDH level (p  0.002; 7.0 versus 11.0 months), a nonepi-
thelial histology (p  0.0001; 7.0 versus 11.0 months), stage
III to IV disease (p  0.0001; 8.5 versus 14.0 months), and
therapy with the best supportive care (p  0.0001; 7.0, 11.5,
and 21.0 months for the best supportive care, the chemother-
apy, and the multimodality therapy group, respectively) for
all the patients.
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In the best supportive care group, univariate analysis
indicated that the presence of smoking history (p  0.049;
5.0 versus 7.0 months), a poor KPS (p  0.0001; 2.0 versus
9.0 months), a right site tumor (p 0.036; 5.0 versus 9.0 months),
a high WBC count (p  0.008; 4.0 versus 8.0 months), low
hemoglobin level (p  0.015; 5.0 versus 8.0 months), a high
LDH level (p  0.008; 3.0 versus 8.0 months), a nonepithelial
histology (p 0.011; 5.0 versus 7.0 months), and stage III to IV
disease (p  0.0001; 5.0 versus 9.0 months) were significantly
related to a poor prognosis. A poor KPS (p 0.0001; 5.4 versus
13.0 months), a high platelet count (p  0.038; 10.0 versus
12.0 months), a high WBC count (p  0.022; 8.0 versus 12.0
months), a high-LDH level (p  0.027; 9.0 versus 12.0
months), a nonepithelial histology (p  0.046; 10.0 versus
12.0 months), and stage III to IV disease (p  0.010; 10.0
versus 14.0 months) were related to a poor prognosis for
the chemotherapy group. The presence of smoking history
(p  0.022; 10.0 versus 41 months), a right site tumor (p 
0.016; 8.0 versus 41.0 months), and a mixed subtype (p 
0.035; 10.0 versus 41.0 months) were associated with a
poor prognosis in the multimodality therapy group.
Multivariate Analysis Results
After adjusting for therapy in a Cox model, a KPS70,
a right side tumor, serum LDH 500 IU1, a nonepithelial
subtype, stage III to IV disease were associated with a poor
prognosis for all the patients (Table 2). A KPS 70, serum
LDH 500 IU1, a nonepithelial subtype, and stage III to IV
disease were related to a poor prognosis for the best support-
ive care group (Table 3). The unfavorable prognostic factor
for the chemotherapy group was only a KPS 70 (Table 4).
The statistician thought that stage has more clinical impor-
tance than smoking on MPM prognosis. Because of that stage
was chosen instead of smoking history for multivariate model
in the multimodality therapy group. The mixed subtype and a






Therapy Group Test Value
No 71 147 17
Mean age, years 63.6  11.0 (33–83) 58.5  11.1 (26–80) 49.7  10.7 (33–69) F12.27; p<0.0001
Male : Female 36:35 75:72 10:7 20.397; p0.820
Asbestos exposure, n (%) 60 (84.5) 132 (89.8) 13 (76.5) 23.109; p0.211
Smoking history, n (%) 29 (40.8) 59 (40.1) 9 (52.9) 21.039; p0.595
Weight loss, n (%) 37 (52.1) 61 (41.5) 2 (11.8) 29.313; p0.009
Chest pain, n (%) 55 (77.5) 119 (81.0) 14 (82.4) 20.427; p0.808
Dyspnoea, n (%) 58 (81.7) 115 (78.2) 13 (76.5) 20.427; p0.808
Mean Karnofsky Performance Status 77.7  10.6 (50–100) 82.5  7.8 (60–100) 86.5  7.0 (80–100) F10.34; p<0.0001
Primary site of disease, n (%)
Right 46 (64.8) 91 (61.9) 6 (35.3) 25.431; p0.066
Left 24 (33.8) 56 (38.1) 11 (64.7)
Histologic subtype, n (%)
Epithelial 46 (64.8) 100 (68.0) 13 (76.5) 25.24; p0.513
Mixed 10 (14.1) 25 (17.0) 4 (23.5)
Sarcomatous 7 (9.9) 9 (6.1) 0 (0.0)
Unidentified 8 (11.3) 13 (8.8) 0 (0.0)
Stage, n (%)
I 24 (33.8) 40 (27.2) 12 (66.7) 216.60; p0.011
II 12 (16.9) 17 (11.6) 1 (5.6)
III 25 (35.2) 61 (41.5) 4 (22.2)
IV 9 (12.7) 29 (19.7) 0 (0.0)
* Variance analysis and chi-square test were used for statistical analysis.
FIGURE 1. Kaplan–Meier survival curves for the best sup-
portive care, the chemotherapy, and the multimodality ther-
apy group.
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right side tumor were associated with worse prognosis for the
multimodality therapy group (Table 5).
DISCUSSION
MPM is always a fatal malignancy. The overall sur-
vival of patients with MPM varies among different treatment
schedules. The median survival of patients receiving best
supportive care is 8 months10–12 and those receiving chemo-
therapy is about 12 months,2,3,12 whereas the survival of
patients with multimodality treatment is 16 to 25 months.4–7,13
The prognosis for MPM can be predicted by well-
validated parameters. Additionally, the treatment strategy is
determined in part by using known prognostic factors. Vari-
ous patient characteristics have been examined for their
potential effect on the survival of patients with MPM. Per-
formance status,8–10,14–16 histology,4,6,8,9,14–19 stage,6,10,17–19
age,9,10,17,19 and gender6,8,15 were identified as the most im-
TABLE 3. Multivariate Stepwise Logistic Regression Model
for the Best Supportive Care Group*
Variable Risk Ratio 95% CI p
Smoking
No 1
Yes 1.491 0.854–2.606 0.160
KPS
70 1
70 3.832 1.978–7.424 0.0001
Primary site of disease
Left 1
Right 1.672 0.959–2.913 0.070
WBC count, l-1
10 000 1
10 000 1.305 0.749–2.273 0.348
Hemoglobin level, gdL-1
12,8 1
12,8 1.422 0.815–2.483 0.215
LDH, IU-1
500 1
500 2.208 1.192–4.093 0.012
Histologic subtype
Epithelial 1
Others 1.858 1.061–3.256 0.030
Stage
I–II 1
III–IV 2.278 1.244–4.172 0.008
* Multivariate analysis was used for statistical analysis.
WBC, white blood cell; LDH, lactate dehydrogenase.
TABLE 4. Multivariate Stepwise Logistic Regression Model
for the Chemotherapy Group*
Variable Risk Ratio 95% CI p
KPS
70 1
70 4.776 2.725–8.370 0.0001
Histologic subtype
Epithelial 1
Others 1.031 0.686–1.549 0.884
Platelet count, l-1 1
400 000
400 000 1.348 0.912–1.994 0.135
WBC count, l-1 1
10 000
10 000 1.363 0.906–2.050 0.137
LDH, IU-1 1
500
500 1.513 0.998–2.296 0.051
Stage
I–II 1
III–IV 1.357 0.912–2.020 0.132
* Multivariate analysis was used for statistical analysis.
WBC, white blood cell; LDH, lactate dehydrogenase.
TABLE 5. Multivariate Stepwise Logistic Regression Model
for the Multimodality Therapy Group*
Variable Risk Ratio 95% CI p
Primary site of disease
Left 1
Right 4.531 1.233–16.647 0.023
Histologic subtype
Epithelial 1
Others 4.545 1.018–20.290 0.047
Stage
I–II 1
III–IV 1.561 0.310–7.852 0.589
* Multivariate analysis was used for statistical analysis.
TABLE 2. Multivariate Stepwise Logistic Regression Model
for All of the Patients*
Variable Risk Ratio 95% CI p
Weight loss
No 1
Yes 1.051 0.772–1.429 0.753
KPS
70 1
70 4.160 2.695–6.423 0.0001
Primary site of disease
Left 1
Right 1.399 1.016–1.926 0.040
WBC count, l-1
10 000 1
10 000 1.381 0.992–1.921 0.056
LDH, IU-1
500 1
500 1.530 1.078–2.172 0.017
Histologic subtype
Epithelial 1
Others 1.574 1.109–2.235 0.011
Stage
I–II 1
III–IV 1.661 1.199–2.300 0.002
* Multivariate analysis was used for statistical analysis.
WBC, white blood cell; LDH, lactate dehydrogenase.
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portant predictors of prognosis in these studies. However,
smoking history, asbestos exposure, chest pain, weight loss,
laterality, LDH level, platelet count, WBC count, and hemo-
globin level were less frequently observed as prognostic
factors.
Our study evaluated the prognosis and prognostic fac-
tors for the survival of 235 patients with MPM undergoing
varying treatments. We determined that the median survival
time was 7.0, 11.5, and 21.0 months in the best supportive
care group, the chemotherapy group, and the multimodality
therapy group, respectively. Some factors such as KPS, stage,
and age, which are considered before selecting the most
suitable treatment, were different among the groups. Patients
who received multimodality therapy were younger, their KPS
was higher, and their stage was earlier when compared with
the others. Patients who received chemotherapy were
younger than those who received best supportive care, and
their performance status was also better. Therefore, adjust-
ments were made according to the treatment before analysis
and then the prognostic factors were assessed for all the
patients. We identified that a KPS 70, a right side tumor,
serum LDH 500 IU1, a nonepithelial subtype, and stage
III to IV disease were significant independent negative prog-
nostic factors for all the patients. Subsequently, prognostic
factors were identified according to each treatment schedule.
The prognostic importance of an epithelial type versus
nonepithelial types has been often addressed, with a clear sur-
vival advantage for the patient with an epithelial type.4,6,8,9,14–19
A good performance of the patient is also considered important
as a prognostic and predictive factor.8–10,14–16 Additionally, the
prognostic significance of the stage has been shown in many
studies.6,10,17–19 These three factors have been used when
planning clinical trials and identifying the most suitable
patients for chemotherapy and radical surgery. We also iden-
tified the effect of these three factors on the survival of the
patients who received the best supportive care. This analysis
showed that patients with a better performance status, an
epithelial type, and an early-stage tumor had better survival
even when they received no therapy. However, the histology
and stage were not related to prognosis in patients who
received chemotherapy; only KPS was related to prognosis in
these patients. Therefore, chemotherapy should be given to
patients with the best performance status, regardless of their
histologic subtype and stage. However, histology was related
to prognosis in the multimodality therapy group. When the
morbidity and mortality rates are considered, multimodality
treatment should not be performed on mixed and sarcomatous
subtypes.
In our study, the primary site of disease (laterality) was
identified as a prognostic factor for all the patients and for the
multimodality therapy group. The survival of patients with a
left side tumor was better than for those with a right side
tumor. A similar result was obtained in a comprehensive
study that also included patients who received radical sur-
gery.6 Furthermore, authors in this study found that the
survival of patients with asbestos exposure was worse.6 In
this study, although asbestos exposure was not identified as a
prognostic factor, it could be a reason for the laterality of
disease if different amounts of asbestos fiber reached the right
or left pleura due to partial differences in the morphologic
structures of the right and left lung. Christensen et al.20 also
found that patient survival was associated with asbestos fiber
burden in MPM, where patients with either low or high
asbestos burden had a higher risk of death compared with
patients with a moderate fiber burden. However, more studies
are necessary to further elucidate the ability of this variable to
predict survival in MPM.
Laboratory characteristics have been included in many
of the multivariate analyses for MPM and have indicated that
low hemoglobin,15 a high WBC count,8,15,16 elevated plate-
lets,9,14 and elevated LDH9,10 are inversely related to the
survival rate. In this study, hemoglobin, WBC count, and
platelet level were not related with the prognosis. However,
the serum LDH level was identified as a prognostic factor for
all the patients and for the best supportive care group. This
parameter may be a marker of disease activity.
Although the mean patient age was different among the
groups, age was not identified as a prognostic factor, which
was contrary to some other studies.9,10,17,19 The male:female
ratio was similar due to the environmental asbestos exposure
in our study. Men had a similar survival to women in this
study, despite being associated with poor prognosis in some
other studies.6,8,15 Patients with MPM mostly present with
symptoms such as chest pain, dyspnea, weight loss, anorexia,
lethargy, and night sweat. Most of these symptoms are indicators
of advanced disease. Weight loss was more frequent in patients
who received best supportive care and chemotherapy than in
those who received multimodality therapy. Additionally, these
patients had advanced stage disease; however, weight loss was
not identified as a prognostic factor.
There has been interest in finding a biomarker that has
value in the prognosis of MPM. The relationship between
numerous overexpressed molecular markers and prognosis
has recently been reported in patients with MPM.21–24 These
markers will allow more targeted treatments. Studies are
necessary to further elucidate the ability of these variables to
predict survival in MPM.
In conclusion, we investigated the various pretreatment
clinical and laboratory characteristics affecting the survival of
patients with MPM according to their treatment schedules,
including those treated with best supportive care, chemother-
apy, and multimodality therapy. However, we did not eval-
uate treatment effectiveness as a prognostic factor. As has
been observed in other studies, patients who had an epithelial
subtype, a good KPS, and early-stage tumors had a better
prognosis, even if they did not receive any treatment. The
only prognostic factor for the chemotherapy group was KPS.
The histologic subtype and stage of the tumor were not
related to the prognosis in this group. A mixed subtype and a
right side tumor were unfavorable prognostic factors for the
multimodality therapy group. These findings may be useful in
counseling patients and in planning further studies.
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